Barry Investment Advisors LLC Sells 19,916 Shares of Pfizer Inc. (NYSE:PFE)

Barry Investment Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 154,871 shares of the biopharmaceutical company's stock after selling 19,916 shares during the quarter. Barry Investment Advisors LLC's holdings in Pfizer were worth $3,924,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PFE. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares in the last quarter. Norges Bank bought a new position in Pfizer in the 4th quarter valued at approximately $2,328,986,000. Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Pfizer by 7.7% in the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Pfizer stock traded down $0.13 during mid-day trading on Friday, hitting $25.65. The stock had a trading volume of 34,838,317 shares, compared to its average volume of 41,846,522. The firm has a market capitalization of $145.83 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.94 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm's 50 day moving average is $23.89 and its 200 day moving average is $24.79. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.82 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Redburn Atlantic lowered their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. HSBC lowered their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.